CN1225466C - Ⅰ型钠－氢交换剂(nhe－1)抑制剂 - Google Patents

Ⅰ型钠－氢交换剂(nhe－1)抑制剂 Download PDF

Info

Publication number
CN1225466C
CN1225466C CNB018087256A CN01808725A CN1225466C CN 1225466 C CN1225466 C CN 1225466C CN B018087256 A CNB018087256 A CN B018087256A CN 01808725 A CN01808725 A CN 01808725A CN 1225466 C CN1225466 C CN 1225466C
Authority
CN
China
Prior art keywords
compound
application
tissue
prodrug
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018087256A
Other languages
English (en)
Chinese (zh)
Other versions
CN1426404A (zh
Inventor
W·G·陈
E·D·科克斯
A·古兹曼－佩雷兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of CN1426404A publication Critical patent/CN1426404A/zh
Application granted granted Critical
Publication of CN1225466C publication Critical patent/CN1225466C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preventing Corrosion Or Incrustation Of Metals (AREA)
  • Treatment Of Water By Ion Exchange (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNB018087256A 2000-04-28 2001-02-28 Ⅰ型钠－氢交换剂(nhe－1)抑制剂 Expired - Fee Related CN1225466C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20043200P 2000-04-28 2000-04-28
US60/200,432 2000-04-28

Publications (2)

Publication Number Publication Date
CN1426404A CN1426404A (zh) 2003-06-25
CN1225466C true CN1225466C (zh) 2005-11-02

Family

ID=22741697

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018087256A Expired - Fee Related CN1225466C (zh) 2000-04-28 2001-02-28 Ⅰ型钠－氢交换剂(nhe－1)抑制剂

Country Status (40)

Country Link
EP (1) EP1276737A1 (es)
JP (1) JP2003531900A (es)
KR (1) KR20020093079A (es)
CN (1) CN1225466C (es)
AP (1) AP2002002651A0 (es)
AR (1) AR028375A1 (es)
AU (1) AU2001235896A1 (es)
BG (1) BG107139A (es)
BR (1) BR0110268A (es)
CA (1) CA2407535A1 (es)
CO (1) CO5221125A1 (es)
CR (1) CR6797A (es)
CZ (1) CZ20023408A3 (es)
DZ (1) DZ3310A1 (es)
EA (1) EA004882B1 (es)
EE (1) EE200200615A (es)
GT (1) GT200100064A (es)
HN (1) HN2001000042A (es)
HR (1) HRP20020851A2 (es)
HU (1) HUP0300651A2 (es)
IL (1) IL152075A0 (es)
IS (2) IS6567A (es)
MA (1) MA26897A1 (es)
MX (1) MXPA02010600A (es)
MY (1) MY133842A (es)
NO (1) NO20025132L (es)
NZ (1) NZ521348A (es)
OA (1) OA12256A (es)
PA (1) PA8513301A1 (es)
PE (1) PE20011270A1 (es)
PL (1) PL357765A1 (es)
SK (1) SK14872002A3 (es)
SV (1) SV2002000418A (es)
TN (1) TNSN01065A1 (es)
TR (1) TR200202439T2 (es)
UA (1) UA73348C2 (es)
UY (1) UY26680A1 (es)
WO (1) WO2001083470A1 (es)
YU (1) YU79602A (es)
ZA (1) ZA200208605B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004518686A (ja) * 2001-01-31 2004-06-24 ファイザー・プロダクツ・インク ナトリウム−水素交換輸送体１型阻害剤のエタノラート
EP1456181A1 (en) * 2001-12-19 2004-09-15 Pfizer Products Inc. Methods for preparing sodium-hydrogen exchanger type-1 inhibitors
MXPA04008646A (es) * 2002-05-02 2004-12-06 Pfizer Prod Inc Tratamiento para la diabetes y complicaciones diabeticas con inhibidores del nhe-1.
FR2840302B1 (fr) * 2002-06-03 2004-07-16 Aventis Pharma Sa Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
ES2220185B1 (es) * 2002-07-16 2006-04-01 Consejo Sup. De Investig. Cientificas Nuevo peptido inhibidor del intercambiador na+/h+ (pinhe), y sus aplicaciones.
MXPA05008612A (es) * 2003-02-14 2005-12-05 Smithkline Beecham Corp Compuestos novedosos.
RU2518741C1 (ru) * 2013-03-22 2014-06-10 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "ЮЖНЫЙ ФЕДЕРАЛЬНЫЙ УНИВЕРСИТЕТ" СРЕДСТВО, ИНГИБИРУЮЩЕЕ Na+/H+-ОБМЕН, И ГАЛОГЕНИДЫ 1-ДИАЛКИЛАМИНОЭТИЛ-3-[ЗАМЕЩЕННЫЙ(ДИЗАМЕЩЕННЫЙ) ФЕНАЦИЛ]-2-АМИНОБЕНЗИМИДАЗОЛИЯ

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU739403B2 (en) * 1998-02-27 2001-10-11 Pfizer Products Inc. N-((substituted five-membered di- or triaza diunsaturated ring)carbonyl) guanidine derivatives for the treatment of ischemia

Also Published As

Publication number Publication date
EE200200615A (et) 2004-04-15
WO2001083470A1 (en) 2001-11-08
UA73348C2 (en) 2005-07-15
HN2001000042A (es) 2001-07-09
HUP0300651A2 (hu) 2003-07-28
HRP20020851A2 (en) 2005-02-28
JP2003531900A (ja) 2003-10-28
IL152075A0 (en) 2003-05-29
UY26680A1 (es) 2001-12-28
TR200202439T2 (tr) 2003-02-21
SV2002000418A (es) 2002-07-03
SK14872002A3 (sk) 2004-03-02
AR028375A1 (es) 2003-05-07
OA12256A (en) 2003-11-06
CA2407535A1 (en) 2001-11-08
MA26897A1 (fr) 2004-12-20
PA8513301A1 (es) 2003-09-05
EA200201023A1 (ru) 2003-02-27
CO5221125A1 (es) 2002-11-28
PE20011270A1 (es) 2001-12-12
GT200100064A (es) 2002-03-22
CR6797A (es) 2004-05-17
BG107139A (bg) 2003-07-31
NO20025132D0 (no) 2002-10-25
AU2001235896A1 (en) 2001-11-12
IS6567A (is) 2002-09-24
EP1276737A1 (en) 2003-01-22
EA004882B1 (ru) 2004-08-26
PL357765A1 (en) 2004-07-26
KR20020093079A (ko) 2002-12-12
ZA200208605B (en) 2003-10-24
MXPA02010600A (es) 2003-03-10
YU79602A (en) 2006-05-25
DZ3310A1 (fr) 2001-11-07
IS6588A (is) 2002-10-21
AP2002002651A0 (en) 2002-12-31
CZ20023408A3 (cs) 2004-01-14
NO20025132L (no) 2002-12-12
NZ521348A (en) 2004-09-24
BR0110268A (pt) 2003-12-30
TNSN01065A1 (fr) 2005-11-10
MY133842A (en) 2007-11-30
CN1426404A (zh) 2003-06-25

Similar Documents

Publication Publication Date Title
CN1245974C (zh) 卡维地洛
CN107531682B (zh) B-raf激酶抑制剂的马来酸盐、其结晶形式、制备方法和用途
CN1234705C (zh) 新的羟基吲哚、其作为磷酸二酯酶4抑制剂的应用及其制备方法
JP5589090B2 (ja) 癌ならびに免疫疾患および自己免疫疾患の治療用のアポトーシス誘発剤
JP2017128605A (ja) 抗ウイルス化合物の固体形態
CN1612866A (zh) 无定形和结晶形的氯沙坦钾及其制备方法
CN1976925A (zh) 吡咯基嘧啶erk蛋白激酶抑制剂的前体药物
CN1261887A (zh) 氮杂环丁基丙基哌啶衍生物、中间体以及作为速激肽拮抗剂的用途
CN113735828B (zh) 一种靶向降解egfr的化合物及其制备方法和应用
JP2013537240A (ja) 糖尿病および脂質異常症の処置のための方法および組成物
US20070232650A1 (en) Malate salts, and polymorphs of (3S,5S)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid
CN1225466C (zh) Ⅰ型钠－氢交换剂(nhe－1)抑制剂
US20130197034A1 (en) Salts Of Methyl 2-((R)-(3-Chlorophenyl)((R)-1-((S)-2-(Methylamino)-3-((R)-Tetrahydro-2H-Pyran-3-Yl)Propylcarbamoyl)Piperidin-3-Yl)Methoxy)Ethylcarbamate
CN109897036B (zh) 三唑并吡啶类化合物及其制备方法和用途
CN1039644C (zh) 神经保护性3,4-二氢-2(1h)-喹诺酮类化合物及应用
CN1232452A (zh) Nmda(n－甲基－d－天冬氨酸)拮抗剂
CN1726208A (zh) E－2－甲氧基－n－( 3－{4－[3－甲基－4－( 6－甲基－吡啶－3－基氧基)－苯基氨基]－喹唑啉－6－基}－烯丙基)－乙酰胺的配合物、其制备方法和用途
CN1265652A (zh) 用作速激肽受体拮抗剂的2－酰基氨基丙胺化合物
CN1303379A (zh) 作为氧化氮合酶抑制剂的含稠环取代基的2－氨基吡啶
US7649008B2 (en) Crystal of benzimidazole derivative and process for producing the same
US6852733B2 (en) Sodium-hydrogen exchanger type 1 inhibitor
KR20240006021A (ko) 카보잔티닙의 제조방법
TW315367B (es)
JP2024526242A (ja) チアゾール－ラクタム－スピロ複素環化合物及びその適用
CN1733727A (zh) 结晶卡维地洛、其制备方法、药物组合物和制药用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1056723

Country of ref document: HK